

Together2Goal[®]

AMGA Foundation
National Diabetes Campaign



Monthly Campaign Webinar

April 2020

Today's Webinar

- Together 2 Goal[®] Updates
 - Webinar Reminders
 - AMGA COVID-19 Resources

- Hypoglycemia Prevention Initiative
 - Jeffrey Boord, M.D., MPH of Parkview Physicians' Group



Webinar Reminders

- This webinar was pre-recorded and made available on April 16th
 - www.Together2Goal.org



AMGA COVID-19 Resources



Since the COVID-19 outbreak began, AMGA has worked closely with members, federal agencies, and other healthcare entities to respond to this challenge and to make sure our member medical groups and health systems have the most up-to-date information and resources.

Here are current tactics and tools from members, our latest advocacy efforts, updated federal policies, and resources from payers and others.

Member Frontline Tactics

Tips, tools, and resources from AMGA members

[Learn More](#)

AMGA Advocacy

Our latest efforts for members on issues related to COVID-19

[Learn More](#)

Chronic Care Resources

Resources for treating vulnerable populations

[Learn More](#)

Federal Policies and Guidance

The most up-to-date documents and tools

[Learn More](#)

Payer Resources

Communications from the payer community

[Learn More](#)

Other Resources

Resources from the World Health Organization and other healthcare interest groups

[Learn More](#)

Today's Featured Presenter

Jeffrey Boord, M.D., MPH



Chief Quality and Safety Officer
Parkview Physicians' Group

Reducing the Incidence of Hypoglycemia

Jeffrey Boord, MD, MPH
Chair, Hypoglycemia Prevention
Initiative Steering Committee

April 2020

Key Messages

- **ASK** about hypoglycemia
 - Ask about hypoglycemia events and the “why” behind them
- **SET** appropriate glycemic targets
 - Engage with your patient, individualize goals
- **MODIFY** therapy where appropriate
- **EDUCATE** your patients
 - Regarding recognition, monitoring, treatment, and prevention
- **MONITOR** clinically and reassess at future visits

Definition of Hypoglycemia



Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Statement of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange

Level	Glycemic Criteria/Description
Level 1	Glucose < 70 mg/dL (3.9 mmol/L) and Glucose \geq 54 mg/dL (3.0 mmol/L)
Level 2	Glucose < 54 mg/dL (<3.0 mmol/L)
Level 3	A severe event characterized by altered mental and/or physical status requiring assistance

Definition of Hypoglycemia

Level	Glycemic Criteria	Description
Hypoglycemia alert value (level 1)	≤ 70 mg/dL (3.9 mmol/L)	Sufficiently low for treatment with fast-acting carbohydrate and dose adjustment of glucose-lowering therapy
Clinically significant hypoglycemia (level 2)	< 54 mg/dL (3.0 mmol/L)	Sufficiently low to indicate serious, clinically important hypoglycemia
Severe hypoglycemia (level 3)	No specific glucose threshold	Hypoglycemia associated with severe cognitive impairment requiring external assistance for recovery

International Hypoglycemia Study Group. Diabetes Care 2017;40:155-157

The Burden of Hypoglycemia

Hypoglycemia accounted for **300,000 ER** visits in 2009 among T1D and T2D patients

Hypoglycemia is the **largest single barrier** to achieving glycemic control in diabetes

The prevalence and impact of hypoglycemia is **substantially underappreciated**

- Incidence of hypoglycemia among patients with T2D on insulin is, on average, **23 mild or moderate events** and **1 severe episode** per year
- Patients with T1D have hypoglycemia about **2-3X** more often than patients with T2D
- **4-10% of deaths** in patients with T1D are caused by hypoglycemia
- Hospitalization as a result of hypoglycemia is associated with a **18.1% 30-day readmission rate** and a **5% 30-day mortality rate**

Seaquist ER, et al. Hypoglycemia and diabetes: a report of a workgroup of the ADA and the Endocrine Society. Diabetes Care 23:1384-1395, 2013
Lash, RW, et al. Preventing hypoglycemia in type 2 diabetes. J Clin Endocrinol Metab 103:1-4, 2018

The Burden of Hypoglycemia

- Insulin and oral insulin secretagogues (sulfonylureas) are among the top 3 medication classes that cause emergent hospitalization due to adverse drug events
- Severe hypoglycemic episodes are associated with higher risk of CV events mortality in patients with diabetes
 - Relationships between hypoglycemia, CV events, and mortality are complex
- Hypoglycemia can contribute to cognitive dysfunction, arrhythmias, and autonomic dysfunction
- Hypoglycemia increases the risk of falls and automobile accidents
- Fear of hypoglycemia reduces quality of life, increases diabetes-related distress, and may impact productivity and work

Seaquist ER, et al. Hypoglycemia and diabetes: a report of a workgroup of the ADA and the Endocrine Society. *Diabetes Care* 23:1384-1395, 2013

Lash, RW, et al. Preventing hypoglycemia in type 2 diabetes. *J Clin Endocrinol Metab* 103:1-4, 2018

Standl, E, et al. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype

Hypoglycemia Unawareness and Hypoglycemia-Associated Autonomic Failure (HAAF)

- Physiologic response to hypoglycemia
 - Adrenergic response (sweating, tachycardia, tremor, hunger)
 - Suppression of insulin secretion
 - Stimulation of glucagon, epinephrine, GH, cortisol secretion
- HAAF Components
 - Defective glucose counterregulation – attenuated glucagon/epinephrine response
 - Hypoglycemia unawareness – attenuated sympathoadrenal activity and minimal or absent adrenergic response
- HAAF is functional and most often caused by antecedent recurrent iatrogenic hypoglycemia
- HAAF associated with 25-fold increase risk of severe hypoglycemia during intensive glycemic therapy

Risk Factors for Hypoglycemia

- Insulin, sulfonylurea, or meglitinide use
- Prior severe hypoglycemia episodes (esp. requiring ED visit or hospitalization)
- History of high glycemic variability / labile glucose
- Older age
- Longer duration of diabetes
- Stage 3-5 CKD
- Cirrhosis
- Dementia or cognitive impairment
- Recent hospitalization with acute kidney injury
- Very tight control (A1c <6%) or poor control (>9%)
- Food insufficiency/malnutrition

Hung A, et al. Diabetes Care 41:503–512, 2018
Lipska KJ, et al. Diabetes Care 36:3535–3542, 2013

Clinic Case Study

- 72 year old female with cognitive impairment, heart failure with preserved ejection fraction, afib on warfarin anticoagulation, prior stroke, hypertension, neuropathy, pulmonary hypertension on chronic O2 therapy, referred for type 2 diabetes management
- Lives in a group home and is on insulin therapy
- Has been on insulin at least 2 years
- A1c: 6.4%, creatinine: 0.7
- Current regimen: Glargine, 35 units, daily in the morning
- Caregiver monitors glucose 3x/day at breakfast, supper, and bedtime
- Eats 3 meals a day and reports good appetite

Hypoglycemia – History

- Self-monitoring of blood glucose
 - Frequency, timing
 - Recent values/log
- Episodes of hypoglycemia
 - Any <70 mg/dl?
 - Any severe hypoglycemia?
 - Context: Diet, activity, medication use, timing
- Hypoglycemia unawareness
 - Can you feel it when your blood sugar is low?
 - Have you had a low reading but no symptoms?
- Self-management
 - What do you do when your blood sugar is low?
 - Do you carry around glucose tablets? Do you have a glucagon kit?
- Nutrition
 - Diet history, weight trend
 - Issues with food insufficiency

Clinic Case Study, Pt. 2

- Caregiver reports patient has hypoglycemia at least 2 times a week during the day, usually before supper or in the morning
- She does not reliably note symptoms during episodes
- Patient has not had any recent hospitalizations or ED visits due to hypoglycemia

2020 ADA Standards: Hypoglycemia

- Individuals at risk for hypoglycemia should be asked about symptomatic and asymptomatic hypoglycemia at each encounter. **C**
- Glucose (15–20 g) is the preferred treatment for the conscious individual with blood glucose ≤ 70 mg/dL [3.9 mmol/L]), although any form of carbohydrate that contains glucose may be used. **B**
- Glucagon should be prescribed for all individuals at increased risk of level 2 hypoglycemia, defined as blood glucose < 54 mg/dL (3.0 mmol/L), so it is available should it be needed. Caregivers, school personnel, or family members of these individuals should know where it is and when and how to administer it. Glucagon administration is not limited to health care professionals. **E**

ADA Standards of Medical Care in Diabetes. Diabetes Care 2020 Jan; 43(Supplement 1): S66-S76

2020 ADA Standards: Hypoglycemia

- Hypoglycemia unawareness or one or more episodes of level 3 hypoglycemia should trigger reevaluation of the treatment regimen. **E**
- Insulin-treated patients with hypoglycemia unawareness, one level 3 hypoglycemic event, or a pattern of unexplained level 2 hypoglycemia should be advised to raise their glycemic targets to strictly avoid hypoglycemia for at least several weeks in order to partially reverse hypoglycemia unawareness and reduce risk of future episodes. **A**
- Ongoing assessment of cognitive function is suggested with increased vigilance for hypoglycemia by the clinician, patient, and caregivers if low cognition or declining cognition is found. **B**

ADA Standards of Medical Care in Diabetes. Diabetes Care 2020 Jan; 43(Supplement 1): S66-S76

For a Patient at Risk for Hypoglycemia

Determine appropriate glycemic goals with patient / caregiver

- Glycemic targets: A1c, FSBG ranges
- Explicit goal to minimize/ prevent hypoglycemia

Determine appropriate pharmacotherapy

- Change medications
- Modify dosing

Educate patient / caregiver and monitor

- FSBG monitoring
- Prescribe glucagon, when appropriate
- Clinical follow up
- When to notify provider between visits

Approach to the Management of Hyperglycemia

Patient / Disease Features

More stringent ← A1C 7% → Less stringent

Risks potentially associated with hypoglycemia and other drug adverse effects

low high

Disease duration

newly diagnosed long-standing

Life expectancy

long short

Important comorbidities

absent few / mild severe

Established vascular complications

absent few / mild severe

Patient attitude and expected treatment efforts

highly motivated, excellent self-care capabilities less motivated, poor self-care capabilities

Resources and support system

readily available limited

Usually not modifiable

Potentially modifiable

Older Adults – Treatment Goals

Overall Health Category		Group 1	Group 2	Group 3
		Good health	Intermediate health	Poor health
Patient characteristics		No comorbidities or 1-2 non-diabetes chronic illnesses* and No ADL ^ε impairments and ≤1 IADL impairment	3 or more non-diabetes chronic illnesses* and/or Any one of the following: mild cognitive impairment or early dementia ≥2 IADL impairments	Any one of the following: End-stage medical condition(s)** Moderate to severe dementia ≥2 ADL impairments Residence in a long-term nursing facility
<p>Reasonable glucose target ranges and HbA1c by group</p> <p>Shared decision-making: individualized goal may be lower or higher</p>				
Use of drugs that may cause hypoglycemia (e.g., insulin, sulfonylurea, glinides)	No	Fasting: 90–130 mg/dL Bedtime: 90–150 mg/dL <7.5%	Fasting: 90–150 mg/dL Bedtime: 100–180 mg/dL <8%	Fasting: 100–180 mg/dL Bedtime: 110–200 mg/dL <8.5% [‡]
	Yes ^ε	Fasting: 90–150 mg/dL Bedtime: 100–180 mg/dL ≥7.0 and <7.5%	Fasting: 100–150 mg/dL Bedtime: 150–180 mg/dL ≥7.5 and <8.0%	Fasting: 100–180 mg/dL Bedtime: 150–250 mg/dL ≥8.0 and <8.5% [‡]

For a Patient at Risk for Hypoglycemia

Determine appropriate glycemic goals with patient / caregiver

- Glycemic targets: A1c, FSBG ranges
- Explicit goal to minimize/ prevent hypoglycemia

Determine appropriate pharmacotherapy

- Change medications
- Modify dosing

Educate patient / caregiver and monitor

- FSBG monitoring
- Prescribe glucagon, when appropriate
- Clinical follow up
- When to notify provider between visits

Patient on glyburide or glimepiride

Change to shorter acting SU (glipizide) or meglitinide

Switch to lower risk agent

Reduce dose or stop agent

Patient on Insulin

Reduce dose or frequency

Modify insulin preparation

Reduce/eliminate prandial or correction insulin dosing

Diabetes Medications with Low Hypoglycemia Risk

- DPP-4 inhibitors
- GLP-1 Agonists
- Metformin
- SGLT-2 Inhibitors
- Thiazolidinediones (TZDs)
- Meglitinides (lower risk than SU)

Tapering Advice*

- Set blood glucose and A1c targets, plus thresholds for returning to previous dose, restarting drug, or maintaining dose
- Develop tapering plan with patient / caregiver
- Doses may be increased or medication restarted at any time if blood glucose persists above individual target or symptomatic hyperglycemia returns

*deprescribing.org- antihyperglycemics deprescribing algorithm:
<https://deprescribing.org/wp-content/uploads/2017/11/AHG-deprescribing-algorithms-2017-English.pdf>

For a Patient at Risk for Hypoglycemia

Determine appropriate glycemic goals with patient / caregiver

- Glycemic targets: A1c, FSBG ranges
- Explicit goal to minimize/ prevent hypoglycemia

Determine appropriate pharmacotherapy

- Change medications
- Modify dosing

Educate patient / caregiver and monitor

- FSBG monitoring
- Prescribe glucagon, when appropriate
- Clinical follow up
- When to notify provider between visits

Patient & Caregiver Education

- Signs and symptoms of hypoglycemia
- Hypoglycemia unawareness
- Treatment of hypoglycemia with oral carbohydrates or glucagon
- Risk factors for hypoglycemia
- Dietary factors
 - Carbohydrates and blood glucose
- Understand diabetes medications
 - How they work, how to take them, when they may need adjustment
- Exercise management
- Glucose Monitoring

<http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html?loc=lwd-slabnav>
<http://clinical.diabetesjournals.org/content/30/1/38>

Hypoglycemia Prevention Initiative

Endocrine Society Prioritizes Hypoglycemia Prevention

Objective: increase national awareness of hypoglycemia and facilitate joint action by stakeholders to reduce its incidence

Established the Hypoglycemia Quality Collaborative (HQC)

Coalition of diabetes stakeholders including medical specialty societies, payers, industry, patient advocates, diabetes educators, and research organizations

Developed the HQC Strategic Blueprint

Provides a comprehensive framework for reducing the incidence of hypoglycemia

Implementing Outpatient Quality Improvement Pilot

A project testing the impact of risk assessment and education on the incidence of hypoglycemia in patients with T2D on insulin or sulfonylureas in the primary care setting

Partnering with Federal Agencies

A collaborative of Federal agencies (FDA, CMS, VA, HHS), Endocrine Society, and quality improvement organizations for raising awareness, improving surveillance, and improving quality of care

Hypoglycemia Quality Collaborative


LAUNCHED JANUARY 2016 BY THE ENDOCRINE SOCIETY

18 Organizations Participate in the Hypoglycemia Quality Collaborative

- Abbott Diabetes Care Inc.
- Aetna
- American Association of Clinical Endocrinologists
- American Association of Diabetes Educators
- American College of Physicians
- American Diabetes Association
- AstraZeneca
- Close Concerns
- Dexcom
- Johnson & Johnson
- Joslin Diabetes Center
- Juvenile Diabetes Research Foundation
- Lilly
- Medtronic Diabetes
- Merck & Co
- Novo Nordisk
- Pharmacy Quality Alliance
- T1D Exchange

HQC Strategic Blueprint

HQC Strategic Blueprint to Reduce the Incidence of Hypoglycemia



Hypoglycemia Prevention Initiative Objectives

- 1. Increase Outpatient Hypoglycemia Surveillance & Risk Assessment**
 - Integrate risk assessment into clinical workflow in primary care
 - Develop outpatient hypoglycemia quality measures
- 2. Improve Management of Patients on Insulin and Sulfonylureas**
 - Provide clinical decision support tools to guide assessment of appropriate A1c goals and medication management options
 - Use shared decision making to set goals and modify treatment
 - Provide educational tools to help patients identify and manage hypoglycemia
- 3. Align Provider Reimbursement to Promote Best Practices**
 - Incorporate clinical improvement activities and quality measures into value-based reimbursement programs
 - Incentivize care teams that provide high-quality care

Environmental Scan Supports Development of the Initiative

- Clinicians have a general lack of awareness of resources to identify, assess, and manage patients at high risk for hypoglycemia
- A few risk assessment tools exist but are not systematically incorporated in clinical workflow
- Educational resources are available but rarely used
- There are no outpatient quality measures on hypoglycemia and there is a clinical need to develop them

Robert W Lash, Deborah O Lucas, Judit Illes; Preventing Hypoglycemia in Type 2 Diabetes, *The Journal of Clinical Endocrinology & Metabolism*, <https://doi.org/10.1210/jc.2017-02804>

Providers Face Challenges Managing Hypoglycemia

Individualized Goals

- I'm not convinced that an A1c less than 7% is good for everyone. The goal is to accomplish the best A1c possible without hypoglycemia, without too much cost, without too much finger pricking, and without too much weight gain.
- I used to believe that lower A1c was better. Last few years I have seen patients with hypoglycemia and changed my practice to decrease hypoglycemia. I don't push for an A1c goal less than 7% for elderly patients. Cost of medications is an issue. Push target A1c down less than 7% and cost of meds increases.

Medication Modification

- Protocols on how to manage polypharmacy and switch meds to avoid hypoglycemia would be nice. Biggest challenge is knowing how to safely reduce insulin intake while still controlling their condition
- Biggest challenges with elderly patients are managing polypharmacy and multiple comorbidities, patient concerns on cost of medication, and patient access to enough glucose testing strips for SMBG.

Educating Providers and Patients

- I think it would be helpful to have patient education materials for hypoglycemia because patients are conditioned to think that they need to be treated for everything.
- Physicians need to know what medicines patients are on, assess risk of hypo (age, renal function, medications), which insulins are better to reduce risk of hypo, and patient goals and expectations.

Patients Report Lack of Education on Hypoglycemia

Fear and Knowledge of Hypoglycemia and Patient Quality of Life

- It's very scary living alone and having hypoglycemia.
- I didn't really learn about hypo until getting involved in peer support groups.
- Hypoglycemia is not always about being below a certain number, but often relative.
- I quit my job years ago and am now in a job that allows me to eat every few hours.

Avoiding Episodes

- I don't find them [hypoglycemic episodes] always so predictable.
- I don't like to take instant sugar/soda. It [treatment] is a little more complicated than just having more carbs, sometimes it's a lack of protein.
- Most episodes happen in the middle of the night

Patient Experience with Medical Care

- I think PCPs believe that even with testing, most diabetics are not going to test their blood or be advocates.
- My PCP never asks about low blood sugar, my endocrinologist always does (and handles all my medications).

Response to Educational Materials

- When I saw these, I was jumping up and down saying "wow I didn't know that" though I consider myself very educated from Diabetes Sisters and self-education.

Hypoglycemia Prevention Study (HypoPrevent)

HypoPrevent is a Component of the Hypoglycemia Prevention Initiative

The **Hypoglycemia Prevention Study**, a central component of the Initiative, is designed to test a dual-pronged intervention in primary care practices to:

1. Identify at-risk patients
2. Assess methods that decrease risk
 - a) Individualizing A1c goals
 - b) Changing medications

Research Questions & End Points

1. Can the hypoglycemia reduction intervention be integrated into primary care workflow?
2. What is the impact of the use of the hypoglycemia reduction intervention on provider behavior and patient outcomes?
3. What is the impact of the use of the hypoglycemia reduction intervention on the size of the at-risk population?

HypoPrevent Will Evaluate a Two-Pronged Intervention

Hypoglycemia Risk Tool

- Identifies patients potentially at risk of medication-related hypoglycemia

Hypoglycemia Reduction Clinical Decision Support Tool


- Supports providers in assessing patients, care planning, and monitoring and ongoing evaluation focusing on:
 - Shared decision-making
 - Individualization of A1c goals
 - Medication management changes

Study Workflow

- Identify patients 65 years old and older with T2D
 - Includes prescription for insulin and/or sulfonylureas
 - Includes A1c of < 7% in previous 6 months
 - Excludes patients on insulin less than 3 months and/or with limited life expectancy of < 12 months

- Invite patients to participate in the study via telephone outreach
- Obtain patient informed consent in-person during Baseline visit

- At Baseline visit and subsequent follow-up visits:
 - Patients complete surveys assessing impact of hypoglycemia and self-efficacy
 - Providers use information on the Decision Support Tool for clinical decision-making
 - Patients and providers either engage in 1) shared decision-making discussion on an individualized A1c target and/or modifications to treatment to reduce risk of hypoglycemia or 2) assess progress to changes to reduce risk of hypoglycemia
- Recommended frequency of follow-up visits is every three months



HypoPrevent Recruitment & Interim Analysis

Overview of Study Site: Pottstown Medical Specialists, Inc.

Overview

PMSI is a physician-owned multispecialty group practice with offices in Berks and Montgomery Counties in Southeastern Pennsylvania. They are committed to delivering the highest quality medical healthcare through the coordination of properly planned, managed and utilized medical services. PMSI has accreditation as a Diabetes Self-Management Support and Education (DSMES) service through AADE and is a recognized provider of the CDC's National Diabetes Prevention Program.

A certified diabetes educator (CDE) coordinates the study across the participating PMSI practices. The office manager ("site coordinator") in each practice and each participating provider was trained on the conduct of the study using a "train the trainer" approach. After training was complete, the first step was to identify and enroll patients into the study.

1,063

Total Patients 65+ with
T2D

15


Total Participating
PMSI Providers

5

Total Participating
Locations

Enrollment Period


The enrollment period was extended 3 times due to slower than expected enrollment



*Enrolled declined in September due to unforeseen loss of PMSI staff member (Avalere notified 9/23)

** Only patients enrolled prior to 11/8 are included in Interim Report (n=3 for November).

Demographic Data for Enrolled Patient Population*



Median age = 73; Mean age = 75

Patient Sex

Sex	N	%
Female	42	68%
Male	20	32%

n=62¹

- **Race**

- White: 95% (60/63)
- Black or African American: 3% (2/63)
- 2 or more races: 2% (1/63)


- **Ethnicity**

- Non-Hispanic: 98% (60/61)
- Hispanic: 2% (1/61)

- **Preferred Language:** 100% English (n=62)


¹ n reflects number of records reporting this data.
* Based on patients enrolled prior to November 8, 2019

Demographic Data for Enrolled Patient Population*



Data reported by PMSI indicates that almost all (42/43) patients with Medicare reported having Part D coverage.

Demographic Data for Enrolled Patient Population



- **50/63 (79%)** of patients reported at least 1 comorbid condition
- Of those reporting a comorbid condition, **25/50 (50%)** reported more than 1 comorbid condition


Duration of Diabetes

- 29 of 63 (46%) patients reported a value for duration of diabetes
- Values reported range from 4 to 27 years with the median duration being 10 years


*Other conditions include Parkinson's Disease, Breast Cancer, CAD/OSA

Baseline Visit: Shared Decision-Making, A1c Goal Setting, and Medication Changes

97% (61/63) of enrolled patients had an SDM discussion at their baseline visit.



Patients may have had their medications changed during different types of conversations with their provider.



While almost a third of patients with an SDM discussion (19/61) had a medication change made either during the visit or during a follow-up phone call or in office visit, many of them (11/19) did **not** have an individualized A1c goal set during the baseline visit. We will continue to explore the reasons for this care decision, including potential alternative metrics to A1c being used to measure successful treatment changes.

Outpatient Hypoglycemia Quality Measures

Outpatient Hypoglycemia QMs

- Proportion of Patients Who Were Assessed to be at Greater Risk for Hypoglycemia
- Educational Intervention for Patients at Greater Risk for Hypoglycemia
- Patient Reported Level 3 Hypoglycemic Event Requiring Assistance

Outpatient Hypoglycemia QMs

- Published in *Journal of Clinical Endocrinology & Metabolism* (April 2020)
 - Available online
- Develop “instructions” for using measures in practice
 - Implementation manual is in development
- Dissemination of measures to primary care practices

INVITED CONSENSUS STATEMENT

2019 Endocrine Society Measures Set for Older Adults With Type 2 Diabetes Who Are at Risk for Hypoglycemia

Performance Measures for Eligible Clinicians Developed by the Endocrine Society

James L. Rosenzweig,¹ Paul R. Conlin,² Jasmine D. Gonzalvo,³ Stephanie B. Kutler,⁴ Nisa M. Maruthur,⁵ Penelope Solis,⁶ Sandeep Vijan,⁷ Amisha Wallia,⁸ and Robin Fein Wright⁹

¹Hebrew SeniorLife, Roslindale, MA 02131; ²Medical Service, VA Boston Healthcare System, West Roxbury, Massachusetts 02132; ³College of Pharmacy, Purdue University, Indianapolis, Indiana 46202; ⁴Government & Public Affairs, Endocrine Society, Washington, DC 20036; ⁵General Internal Medicine, Johns Hopkins University, Baltimore, Maryland 21287; ⁶Avalere Health, Washington, DC 20005; ⁷Institute for Healthcare Policy & Innovation, University of Michigan, Ann Arbor, Michigan 48109; ⁸Center for Diabetes and Metabolism, Northwestern University, Chicago, Illinois 60611; and ⁹Diabetes Sisters, Princeton, New Jersey 08542.

ORCID number: 0000-0002-4664-8019 (J. L. Rosenzweig).

Context: Hypoglycemia in the outpatient setting has a significant financial impact on the health care system and negative impact on a person's quality of life. Primary care physicians must address a multitude of issues in a visit with a person with type 2 diabetes mellitus (T2DM), often leaving little time to ask about hypoglycemia.

Objective: To develop quality measures that focus on outpatient hypoglycemia episodes for patients 65 and older with T2DM, which facilitate a clinician's ability to identify opportunities to improve the quality of care and reduce hypoglycemic episodes.

Participants and Process: A technical expert panel established by the Endocrine Society in March 2019, which includes endocrinologists, primary care physicians, a diabetes care and education specialist/pharmacist, and a patient, developed 3 outpatient hypoglycemia quality measures. The measure set is intended to improve quality of care for patients with T2DM who are at greatest risk for hypoglycemia. The measures were available for public comment in July 2019. A fourth measure on shared decision-making was removed from the final measure set based on public feedback.

Conclusion: A lack of outpatient hypoglycemia measures focusing on older adults with T2DM is a barrier to improving care of people with diabetes and reducing hypoglycemic episodes. This paper provides measure specifications for 3 measures that may be used to focus quality improvement efforts on patients at greatest risk for hypoglycemia. (*J Clin Endocrinol Metab* 105: 1–22, 2020)

Key Words: diabetes, hypoglycemia, older adults, diabetes medications, performance measures, quality improvement, type 2 diabetes

ISSN Print 0021-972X; ISSN Online 1945-7197
Printed in USA

© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.
permissions@oup.com

Received 14 November 2019; Accepted 10 December 2019

First Published Online 11 December 2019

Corrected and Typeset 17 March 2020

Abbreviations: A1c, hemoglobin A1c; ADA, American Diabetes Association; SDH, social determinants of health; SDM, shared decision-making; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TER, technical expert panel.

doi:10.1210/clinem/dgzz250

J Clin Endocrinol Metab, April 2020, 105(4):1–22

<https://academic.oup.com/jcem>

1

Downloaded from <https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/clinem/dgzz250/5873461> by guest on 20 March 2020

How You Can Become Involved

Interested in learning about how your practice can become involved in HypoPrevent? Would you like to be alerted when the study tools and QM implementation guide is available?

Contact

Stephanie Kutler


Director, Advocacy & Policy

skutler@endocrine.org

Hypoglycemia Prevention Initiative Supporters



Abbott



MERCK

Lilly

SANOFI



Thank you!

www.endocrine.org/hypoglycemia-prevention-initiative